Benjamin P. Levy, MD, provides his perspective on the IMpower150 trial evaluating the combination of immunotherapy/antiangiogenic therapy/chemotherapy in advanced lung cancer and considers this patient as a potential candidate for the regimen.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
